Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. | Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 | Founding Date 2010 | Founding Date 2000 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Carlsbad, US HQ | ||
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 17 | Employees 5,60044% increase | Employees 999 | Employees 92716% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 6.6 b | Valuation ($) 12.1 m | Valuation ($) 21.2 b | Valuation ($) 648.3 m | Valuation ($) 6.3 b |
Financial | ||||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $6.8b (FY, 2023) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) $787.6m (FY, 2023) |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods $4.7b (FY, 2023) | Cost of goods €64.3m (FY, 2023) | Cost of goods $9.1m (FY, 2023) |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit $2.2b (FY, 2023) | Gross profit (€2.6m) (FY, 2023) | Gross profit $778.5m (FY, 2023) |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income (€8.4m) (FY, 2023) | Net income ($4.7b) (FY, 2023) | Net income (€260.2m) (FY, 2023) | Net income ($366.3m) (FY, 2023) |
Operating ⚠ | ||||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications 430 (FY, 2021) | Patent Applications 500 (Mar, 2020) | Patent Applications N/A |
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued 270 (FY, 2020) | Patents Issued 233 (May, 2020) | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products 1 (FY, 2023) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 13 (FY, 2023) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2023) |
Funding | ||||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised N/A | Total funding raised $ 1.8b | Total funding raised $ 1.1b | Total funding raised N/A |